Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick F Smith

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Hepatology (Baltimore, Md.)|May 30, 2008
A grapefruit a day for patients infected with hepatitis C?Peter N Morcos, Barbara Brennan, Patrick F Smith
Clinics in Liver Disease|November 27, 2012
Hepatitis C viral kinetics: the past, present, and futureAnushree Chatterjee, Patrick F Smith, Alan S Perelson
Clinical Pharmacology and Therapeutics|July 16, 2024
Extended Model-Informed Drug Development: Beyond Clinical Trials and Regulatory ApprovalMohamed A Kamal, Samit Ganguly, Ananth Kadambi, et al.
Clinical and Translational Science|March 27, 2020
Optimizing COVID-19 Candidate Therapeutics: Thinking Without BordersCraig R Rayner, Patrick F Smith, Kevin Hershberger, et al.
British Journal of Clinical Pharmacology|April 15, 2021
Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometricsJasmine Davda, Kellie Reynolds, John D Davis, et al.
Journal of Clinical Pharmacology|June 5, 2002
Effect of food on the pharmacokinetics of (-) and (+) dOTC when administered as an oral racematePatrick F Smith, Alan Forrest, John M Adams, et al.
Diagnostic Microbiology and Infectious Disease|June 7, 2005
Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer centerPatrick F Smith, Brent M Booker, Abayomi B Ogundele, et al.
British Journal of Clinical Pharmacology|April 19, 2020
Dosing will be a key success factor in repurposing antivirals for COVID-19Patrick F Smith, Michael Dodds, Darren Bentley, et al.
Expert Opinion on Drug Metabolism & Toxicology|April 13, 2007
Drug interactions between proton pump inhibitors and antiretroviral drugsSarah M McCabe, Patrick F Smith, Qing Ma, et al.
Journal of Clinical Lipidology|February 16, 2022
Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairmentDavid Kallend, Robert Stoekenbroek, YanLing He, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Hepatology (Baltimore, Md.)|May 30, 2008
A grapefruit a day for patients infected with hepatitis C?Peter N Morcos, Barbara Brennan, Patrick F Smith
Clinics in Liver Disease|November 27, 2012
Hepatitis C viral kinetics: the past, present, and futureAnushree Chatterjee, Patrick F Smith, Alan S Perelson
Clinical Pharmacology and Therapeutics|July 16, 2024
Extended Model-Informed Drug Development: Beyond Clinical Trials and Regulatory ApprovalMohamed A Kamal, Samit Ganguly, Ananth Kadambi, et al.
Clinical and Translational Science|March 27, 2020
Optimizing COVID-19 Candidate Therapeutics: Thinking Without BordersCraig R Rayner, Patrick F Smith, Kevin Hershberger, et al.
British Journal of Clinical Pharmacology|April 15, 2021
Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometricsJasmine Davda, Kellie Reynolds, John D Davis, et al.
Journal of Clinical Pharmacology|June 5, 2002
Effect of food on the pharmacokinetics of (-) and (+) dOTC when administered as an oral racematePatrick F Smith, Alan Forrest, John M Adams, et al.
Diagnostic Microbiology and Infectious Disease|June 7, 2005
Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer centerPatrick F Smith, Brent M Booker, Abayomi B Ogundele, et al.
British Journal of Clinical Pharmacology|April 19, 2020
Dosing will be a key success factor in repurposing antivirals for COVID-19Patrick F Smith, Michael Dodds, Darren Bentley, et al.
Expert Opinion on Drug Metabolism & Toxicology|April 13, 2007
Drug interactions between proton pump inhibitors and antiretroviral drugsSarah M McCabe, Patrick F Smith, Qing Ma, et al.
Journal of Clinical Lipidology|February 16, 2022
Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairmentDavid Kallend, Robert Stoekenbroek, YanLing He, et al.
Pageof 7